Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Three recent drug approvals have shifted the landscape in the second-line setting for renal cell carcinoma, and researchers are now setting their sights on transforming upfront care.

Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer, discusses highlights from the 2016 ASH Annual Meeting focused on the area of mantle cell lymphoma (MCL).

To great fanfare, Hackensack Meridian Health of New Jersey and Memorial Sloan Kettering Cancer Center announced a co-branding partnership that they say would lead to highly fruitful collaborative research and make hundreds of clinical trial opportunities available to their patients.

Dmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the novel approaches with immunotherapy that he would like to explore in the future treatment of patients with gynecologic cancers.

Immunotherapy may be having a moment in the changing landscape of bladder cancer, but expert Gopa Iyer, MD, advises that there is much research to be done before physicians replace chemotherapy with these agents upfront.

For patients with metastatic castration-resistant prostate cancer, the radiopharmaceutical radium-223 dichloride has proven to be an efficacious bone-targeted agent.

Dean F. Bajorin, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy approaches for patients with metastatic and muscle-invasive bladder cancer.

Immunotherapy combinations have significant potential as treatment for patients with renal cell carcinoma.

Gopa Iyer, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy options for patients with bladder cancer, but mentions how other agents are evolving the landscape. Iyer shared this insight during the 2016 OncLive® State of the Science Summit on Genitourinary Cancers.

Jonathan E. Rosenberg, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the emergence of immunotherapies in the field of bladder cancer, including atezolizumab (Tecentriq), nivolumab (Opdivo), and pembrolizumab (Keytruda). Rosenberg shared this at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the potential combinations that could be explored with novel agents in the treatment of patients with acute myeloid leukemia.

Dana E. Rathkopf, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses agents being explored as treatments for patients with prostate cancer, including apalutamide and PARP inhibitors.

Identifying biomarkers to determine who should receive chemotherapy, targeted agents, and immunotherapy is just one of several obstacles the prostate cancer community is currently facing.

How oncologists can translate their increased understanding of the biology of prostate cancer into clinical practice is a question being raised currently in the field, explains Howard I. Scher, MD, adding, that the emergence of liquid biopsies could possibly be one way to tackle the issue.

A number of clinical trials are seeking to identify beneficial therapeutic outcomes in patients with prostate cancer who are resistant to androgen receptor–targeted agents.

The PD-1/PD-L1 inhibitors moving through the pipeline in bladder cancer will have a lasting impact on the armamentarium in the field, explains Jonathan E. Rosenberg, MD.

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses what novel combinatorial approaches researchers will be explored with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Philip W. Kantoff, MD, chairman of Medicine at Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care winner for Genitourinary Cancer, discusses the role that chemotherapy treatment with docetaxel will continue to have in patients with prostate cancer. Kantoff shared this insight in an interview during the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses understanding the genetics of patients with metastatic castration-resistant prostate cancer.

Gopa Iyer, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses significant points for community oncologists to be aware of when treating patients with bladder cancer with immunotherapy agents.

While immunotherapy continues to make headway in various malignancies, the chemotherapy docetaxel maintains a key role in the treatment of patients with metastatic prostate cancer.

Dana E. Rathkopf, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses mitigating androgen receptor (AR)-resistance in patients with prostate cancer.

Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, discusses resistance to immunotherapy in patients with pancreatic cancer.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements seen with immunotherapy in the treatment of patients with melanoma.

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses considerations for the management of immunotherapy toxicities.

Dmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ways in which immunotherapy is slated to play a major role in multiple cancer types.

Joshua Sabari, MD, medical oncology fellow, Memorial Sloan Kettering Cancer Center, discusses recent findings in immunotherapy as potential treatment for patients with small cell lung cancer.

The SPINET trial is an international, phase III, randomized, double-blind study evaluating the efficacy and safety of lanreotide (Somatuline Depot) plus best supportive care compared with placebo plus best supportive care in patients with well-differentiated, metastatic and/or unresectable, typical or atypical lung neuroendocrine tumors.

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses the high-risk period for rectal tumor regrowth in patients.

Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of the PI3k pathway in patients with metastatic breast cancer.